Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972


Spotlight on Scrip Perspectives 24/25





Focus On Asia


Data Analysis


R&D


Novo Nordisk Rises Again As Amycretin Achieves Rapid Weight Loss

 

The combination drug hit the 22% weight loss mark in just 36 weeks which has lifted the Danish company’s shares after a recent run of disappointing results.

AstraZeneca Sees Canada As Land Of Opportunity With $570m Investment

 
• By 

CEO Pascal Soriot said the deal, which will create more than 700 new jobs, reflected “our strong belief in Canada’s potential as a global hub for life sciences innovation, and the value of public-private collaboration.”

Scrip Asks... What Does 2025 Hold For Biopharma? Part 4: Artificial Intelligence and Data Science

 

More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.

R&D In The IRA Era: Takeda Opts Not To Develop Zasocitinib For Lupus

 

The TYK2 inhibitor is in Phase III development for plaque psoriasis and psoriatic arthritis but the company said it will not pursue late-stage studies in lupus, partly due to the Inflation Reduction Act.

Business


Ascentage Grosses $126.4m In First Biopharma IPO In The US For 2025

 
• By 

The China/US hematologic cancer-focused firm said the offering should give it runway into 2028, perhaps time enough to bring its top two pipeline assets to market in the US.

M&A Values Continued To Decline During Q4 2024

 
• By 

Evaluate data show that the biopharma industry made $9.5bn of acquisitions during the fourth quarter, a third consecutive quarter of decline, although deal volume rose to 33 from Q3’s 29.

AstraZeneca Sees Canada As Land Of Opportunity With $570m Investment

 
• By 

CEO Pascal Soriot said the deal, which will create more than 700 new jobs, reflected “our strong belief in Canada’s potential as a global hub for life sciences innovation, and the value of public-private collaboration.”

Mixed Bag For Biopharma Funding In 2025: Thoughts From J.P. Morgan, Biotech Showcase

 
• By 

Scrip used the J.P. Morgan Healthcare Conference and Biotech Showcase to speak with investors and gauge the health of the capital markets this year.

Scrip Originals


Executives On The Move: Two CEOs, Three CCOs And One COO Among This Week’s Changes

Recent moves in the industry include C-suite changes at Ribometrix and Emyria, plus Arvinas acquires chief commercial officer from Lexicon Pharmaceuticals.

Pipeline Watch: Six Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Stock Watch: J&J, GSK, Lilly Bring J.P. Morgan Cheer

 
• By 

After a less auspicious prelude and a positive start to the biggest healthcare conference of the year, the news flow and investors’ support for biotech initially improved.

Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku

 

Plus deals involving Simcere/AbbVie, Daiichi Sankyo/Glycotope, Telix/ImaginAb, Harbour/Kelun/Windward, Insilico/Menarini, Samsung Bioepis/Teva, HealZen/J&J, Zai Lab/Vertex, Zai Lab/MediLink and Primrose/Serum Institute of India.